Disease relevance of Antineoplaston-A10

• Antineoplaston A10, a human urinary product of minimal toxicity and demonstrable antineoplastic activity, was examined as a modulator of spontaneous mammary tumour development in C3H+ mice [1].
• Our findings indicate that the antineoplaston A10 antitumor effect could be utilized as an effective therapy for breast cancer patients [2].
• The effect of Antineoplaston A10 (AA10), an amino acid derivative isolated from human urine, has been studied on pulmonary adenoma formation resulting from intragastric administration of benzo(a)pyrene(BP) to A/HeJ mice [3].
• One showed massive coagulation necrosis of tumors after intra-arterial infusion of antineoplaston A10 I and the other showed resolution of portal vein tumor thrombosis with systemic infusion of antineoplaston A10 I [4].
• Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report [5].

High impact information on Antineoplaston-A10

• Antineoplaston A10 and AS2-1 are chemically identified and synthesized antineoplastons proven to inhibit cancer cell growth by arresting the cell cycle in the G1 phase and inhibiting tumor growth by reducing mitosis [6].
• We review herein 2 cases of advanced HCC treated with antineoplaston A10 I [4].
• Theoretical investigations on the structure and potential binding sites of antineoplaston A10 and experimental findings [7].
• Studies of the release rate and bioavailability of antineoplaston A10 capsule [8].
• The effect of Tween-80 on the release rate of antineoplaston A10 capsule in vitro was measured [8].

Chemical compound and disease context of Antineoplaston-A10

• OBJECTIVE: To evaluate the response rates, survival and toxicity of treatment with antineoplaston A10 and AS2-1 (ANP) in the first 12 children enrolled in our studies diagnosed with incurable recurrent and progressive multicentric glioma [5].

Biological context of Antineoplaston-A10

• The identification of the major radioactive material as Antineoplaston A10 was confirmed by TLC and analysis of the products of acid hydrolysis and by determination of melting range [9].
• Toxicology studies on antineoplaston A10 injections in cancer patients [10].
• We report here the effects of Antineoplaston A10 and AS2-1 on cell proliferation, cell morphology, cell cycle, and DNA in human hepatocellular carcinoma cell lines [11].

Anatomical context of Antineoplaston-A10

• It was observed by quantitative HPLC analysis that in rats sacrificed 6 h after Antineoplaston A10 administration, between 61% to 69% of the drug was absorbed, whereas between 37% to 28% was found in the stomach and between 2% to 3% was present in the intestinal contents and faeces [9].
• Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report [12].
• Antineoplaston A10 (3-pehnylacetylamino-2,6-piperidinedion) is the first chemically identified antineoplastons and when it is administered orally it is hydrolysed in pancreatic juice to phenylactylglutamine and phenylacetylisoglutamine in the ration of 4 to 1 [11].

Associations of Antineoplaston-A10 with other chemical compounds

• The initial hydrolysis of Antineoplaston A10 (3-phenylacetylamine-2, 6-piperidinedione) yields phenylacetylglutamine and phenylacetylisoglutamine [13].
• The essential biological importance of antineoplastons has motivated the present theoretical and experimental studies on the structure and potential binding sites of Antineoplaston A10, 3-phenylacetylamino-2,6-piperidinedione [7].
• Antineoplaston AS2-1 is a mixture of two products of hydrolysis of Antineoplaston A10 and consists of sodium salts of phenylacetylglutamine and phenylacetic acid in the ratio of 1:4 [14].

Analytical, diagnostic and therapeutic context of Antineoplaston-A10

• Chemoprevention by antineoplaston A10 of benzo(a)pyrene-induced pulmonary neoplasia [3].
• Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats [9].
• Our cases of advanced cancer responded well to combination treatment using chemotherapeutics and irradiation with antineoplaston A10 and AS2-1 in clinical trials being conducted in Kurume University Hospital. We describe herein the clinical cases and discuss the possible mechanism of action of this combination therapy [6].
• METHODS: Antineoplastons, which consist of antineoplaston A10 (A10I) and AS2-1 injections, were given in escalating doses by intravenous injections [15].

References